Oncolytic Viral Therapy to Potentiate Immune Checkpoint Blockade in Immunologically Cold Brain Tumors

The objective of this project is to evaluate the interactions of a clinical-stage RRV (Toca 511) and oncolytic measles virus (MV-NIS) with the endogenous anti-tumor immune response, either as monotherapies or in combination with immune-checkpoint blockade, in murine models of pediatric glioma and medulloblastoma.

Funding Agency: Department of Defense – Peer-Reviewed Cancer Research Program (PRCRP)